NTRA250117C125000
- 36.40
- 0.000.00%
Natera Newsroom
Natera Initiated at Overweight by Barclays
Barclays Initiates Natera(NTRA.US) With Buy Rating, Announces Target Price $200
Natera Insider Sold Shares Worth $12,958,585, According to a Recent SEC Filing
Natera Insider Sold Shares Worth $4,277,735, According to a Recent SEC Filing
Insider Sale: Director at $NTRA (NTRA) Sells 964 Shares
Express News | Natera Shares Are Trading Higher After the Company Announced It Will Reveal New Insights and Innovations for Tissue-free MRD at ASCO GI 2025
BTIG Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $185
Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and Natera (NTRA)
Natera to Present New Data at the 2025 ASCO GI Symposium
Looking Into Natera's Recent Short Interest
The End Of The 60/40 Portfolio
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday
Natera Analyst Ratings
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
Guggenheim Maintains Natera(NTRA.US) With Buy Rating, Announces Target Price $200
Express News | Natera Inc : Guggenheim Raises Target Price to $200 From $170
US MOVERS&SHAKERS Jan 13-Jan 17, 2025
Australia Non-Invasive Prenatal Testing (NIPT) Market Forecast, 2024-2033 With F. Hoffmann-La Roche, Virtus Health, Illumina, BGI, Natera, Monash IVF Group Leading - ResearchAndMarkets.com
Bernstein Keeps Their Buy Rating on Natera (NTRA)
Express News | Natera To Provide Roadmap And Outlook At J.P. Morgan Healthcare Conference